Frequently Answered Questions
3. What exactly is an aluminium adjuvant and why is it necessary
Many of you are not only new to my substack (thank you by the way) but also to the subject of human exposure to aluminium. Of course, my default message to the latter is to read my recent book Imagine You Are An Aluminium Atom and I hope you will do this in good time. However, in the meantime I will try to summarise herein a frequently answered question concerning why aluminium adjuvants are present in vaccines. Those of you wishing to delve deeply into the science of aluminium adjuvants should read our major review of the subject. In this substack I will try to put this subject into the proverbial nutshell.
The majority of human vaccines, for example those on the paediatric schedule, use aluminium adjuvants. The presence of aluminium ensures the efficacy of the vaccine and allows the administration of extremely small quantities of the vaccine antigen. If the same vaccine was injected without the additional presence of an aluminium adjuvant the antigen would be insufficient to elicit any form of immune response. The vaccine would be completely ineffective.
So, how does the aluminium adjuvant perform this ‘medical miracle’, what is its ‘dirty little secret’? How is this possible, especially considering Paul Offit’s assertion that aluminium adjuvants are immunologically inert. Well the answer is quite simple and I have written about this previously in detail. Aluminium is acutely cytotoxic, it kills cells within minutes and hours of their initial exposure. That red mark at the injection site is a signature of cell-death-induced inflammation. The necrotic death of a variety of cells at the injection site sets off an inflammatory response. Immune reactive cells from the body are attracted to the vaccine injection site by cell death. These cells are charged with clearing up the aluminium-induced damage and they achieve this primarily by ‘eating’ all of the dangerous cell debris and this includes ingestion of aluminium adjuvant with or without occluded vaccine antigen. These immune reactive cells including such cells as macrophages are migratory and capable of transporting their potentially toxic cargoes throughout the body. This includes carrying vaccine antigen to the spleen where it initiates an immune response and also carrying aluminium adjuvant to brain tissue where it may be responsible for an encephalopathy. This is how and why aluminium adjuvants are effective in turning, to use Offit’s vernacular, immunologically inert vaccine antigen into something which is both immunologically active and potentially toxic.
Knowing how and why aluminium adjuvants are effective gives us an insight into how the vaccine industry decides how much aluminium to include in a vaccine. Essentially, they do not want too much of an inflammatory response at the vaccine injection site as this could result in potentially severe reactions within a short period of time. Bad publicity for the vaccine! The aluminium content of a vaccine is sufficient to result in a specific level of antibodies to the injected antigen and, hopefully, low enough such that the aluminium does not induce a serious adverse event within the 15 minutes of ‘observation’ following injection of the vaccine. With this in mind the ‘technology’ involved in including aluminium adjuvants in vaccine preparations is so fraught with problems that neither the vaccine manufacturers nor the regulatory agencies (FDA/EMA) have any idea how much aluminium is present in any particular vaccine dose. This is the reality of vaccines that include aluminium adjuvants and this is surely one additional reason why they are dangerous and their use should be stopped immediately pending true safety trials.
I hope that this frequently answered question is useful and will empower you to address further questions on this matter.
PS. My substack is free to all and will remain so. However, I do very much appreciate all paid subscriptions as these are enabling me to continue to be an evangelist for human exposure to aluminium at a highest possible level. I have a voice and you are helping me to speak the truth on aluminium fully supported by high quality peer-reviewed published research. Thank you.
So, it's largely an issue of cost then. Is there an estimate of how much more antigen would be required if no adjuvant was used?
The HPV and HEP (A & B) have unusually high adverse events (different but overlapping patterns) for autoimmune AEs like POTS, etc. in VAERS. Could the included aluminum adjuvants contribute to or drive these adverse events?